Join Gilead-Kite surfing into the future of cell therapy. Listen to Nordic researchers discuss perspectives and future promise of CAR-T in haemato-oncology and solid tumours, CAR-T, TCR, CAR-NK, allo-CAR development and the exciting future of immuno-oncology to combat cancer.
Innehållet i podden är skapat av Gilead Sciences Sweden AB, Hemvärnsgatan 9, 171 54 Solna.
All content for The Cell Therapy Podcast is the property of KITE Gilead and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Join Gilead-Kite surfing into the future of cell therapy. Listen to Nordic researchers discuss perspectives and future promise of CAR-T in haemato-oncology and solid tumours, CAR-T, TCR, CAR-NK, allo-CAR development and the exciting future of immuno-oncology to combat cancer.
Innehållet i podden är skapat av Gilead Sciences Sweden AB, Hemvärnsgatan 9, 171 54 Solna.
How can we trick cancer cells into revealing new antigens; and whats the next cell-type for adoptive therapies?
In this first episode of the Cell Therapy Podcast we talk with Sine Reker Hadrup, professor at Technical University of Denmark about her one of her latest articles in Nature Communication called ‘Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers’ (link: https://www.nature.com/articles/s41467-020-19464-8).
We discuss with Professor Hadrup the methods they used to explore ways to allow cancer cells to display more tumor antigens, and the very clever methods they used to identify them.
Read more about Sine Reker Hadrup here: https://www.healthtech.dtu.dk/english/Research/Research-Sections/Section-XTI
The Cell Therapy Podcast
Join Gilead-Kite surfing into the future of cell therapy. Listen to Nordic researchers discuss perspectives and future promise of CAR-T in haemato-oncology and solid tumours, CAR-T, TCR, CAR-NK, allo-CAR development and the exciting future of immuno-oncology to combat cancer.
Innehållet i podden är skapat av Gilead Sciences Sweden AB, Hemvärnsgatan 9, 171 54 Solna.